Postdoc research program in human health

At Boehringer Ingelheim, our Postdoctoral Research Program in human health gives talented and ambitious scientists the chance to explore cutting-edge science with industry-leading experts. You’ll tackle tough research questions, spark fresh ideas, and pave the way to new therapies and technologies. Together, we’ll lay the foundation for breakthrough medicines that have the potential to transform patients’ lives.

About our postdoctoral research program

The program fosters independent research and provides a framework for postdoctoral researchers to share ideas. The fixed-period positions are an opportunity to:

• Be responsible for research projects
• Publish your work in peer-reviewed scientific journals
• Be in a fully-resourced and well-funded translational research environment
• Receive sponsorship to attend scientific conferences
• Access mentoring and peer program

Ready to join? Requirements for postdoctoral opportunities.

This program is right for you if you’re a:

• Highly motivated scientist with a Ph.D. in a relevant scientific area, such as biology, biotechnology, biochemistry, chemistry, pharmacy, pharmacology, data science or computational biology.
• Creative, innovative, and results-driven scientist who enjoys working in a research team.
• Goal-oriented with strong communication skills (in English) and the ability to explain complex science to colleagues from other disciplines.

Why do your postdoc at Boehringer?

• Make an impact that matters: At Boehringer, postdocs contribute to our robust pipeline.
• Collaborate in a global life science community: We're focused on combining expertise and sharing knowledge across academia and the pharma industry to drive innovation.
• Join a diverse team of scientists: We have R&D sites around the world with people who are curious, creative, and who have a passion for science.
• Grow your career: Our postdoc program is designed to help you shape and enhance your scientific profile.
• Enjoy a supportive environment: Our distinctive culture of collaboration drives us to learn more, do more, and achieve more as researchers and as a company.

Postdoc program locations

The programs are based at our main R&D sites. You can learn more about the specific programs for each location:

• Ridgefield, Connecticut (United States)
• Biberach (Germany)
• Regional Center Vienna (RCV)

Explore open postdoc positions and apply today

Open positions are published on an as-needed basis. Check available positions in our careers web site.

What work has been done by previous postdocs?

If you are curious to learn what type of work postdocs do at Boehringer, you can explore a selection of publications from our postdocs:

• Walter M, Borghardt JM, Humbeck L, Skalic M. Multi-Task ADME/PK prediction at industrial scale: leveraging large and diverse experimental datasets. Mol Inform. 2024; 43(10):e202400079.
• Ponserre M, Ionescu TM, Franz AA, Deiana S, Schuelert N, Lamla T, Williams RH, Wotjak CT, Hobson S, Dine J, Omrani A. Long-term adaptation of prefrontal circuits in a mouse model of NMDAR hypofunction. Neuropharmacology. 2024; 15;254:109970.
• Ries B, Alibay I, Anand NM, Biggin PC, Magarkar A. Automated Absolute Binding Free Energy Calculation Workflow for Drug Discovery. J Chem Inf Model. 2024; 22;64(14):5357-5364.
• Blahetek G, Mayer C, Zuber J, Lenter M, Strobel B. Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells. Mol Ther Methods Clin Dev. 2024; 10;32(3):101280.
• Ries B, Alibay I, Swenson DWH, Baumann HM, Henry MM, Eastwood JRB, Gowers RJ. Kartograf: A Geometrically Accurate Atom Mapper for Hybrid-Topology Relative Free Energy Calculations. J Chem Theory Comput. 2024; 12;20(5):1862-1877.
• Zingman I, Stierstorfer B, Lempp C, Heinemann F. Learning image representations for anomaly detection: Application to discovery of histological alterations in drug development. Med Image Anal. 2024; 92:103067.
• Pinto C, Slavic-Obradovic K, Furweger D, Thaler B, Souabni A, Carotta S, Aichinger M, Reiser U, Impagnatiello MA, Tirapu I. Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics. iScience. 2023; 26(4):106381.
• Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M, Eder T, Neumann T, Jude J, Fellner M, Ebert A, Steininger M, Delwel R, Grebien F, Zuber J. EVI1 drives leukemogenesis through aberrant ERG activation. Blood. 2023; 141(5):453–466.
• Morreale FE, Kleine S, Leodolter J, Junker S, Hoi DM, Ovchinnikov S, Okun A, Kley J, Kurzbauer R, Junk L, Guha S, Podlesainski D, Kazmaier U, Boehmelt G, Weinstabl H, Rumpel K, Schmiedel VM, Hartl M, Haselbach D, Meinhart A, Kaiser M, Clausen T. BacPROTACs mediate targeted protein degradation in bacteria. Cell. 2022; 185:2338-2353.
• Köferle A, Schlattl A, Hörmann A, Thatikonda V, Popa A, Spreitzer F, Ravichandran MC, Supper V, Oberndorfer S, Puchner T, Wieshofer C, Corcokovic M, Reiser C, Wöhrle S, Popow J, Pearson M, Martinez J, Weitzer S, Mair B, Neumüller RA. Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. Cell Rep. 2022; (39):110636.